Health organizations and doctors’ groups are calling on Andy Burnham to cancel a trade deal between the UK and U.S. regarding medicines [1].
The request comes as critics argue the agreement prioritizes the profits of pharmaceutical companies over the health of NHS patients. If the deal remains in place, advocates warn it could lead to a significant increase in preventable mortality across the United Kingdom.
The agreement was signed last December [1]. However, medical groups have since described the terms of the deal as "dangerous" [1]. They said that the framework shifts the balance of power toward drug manufacturers, potentially limiting the NHS's ability to negotiate fair pricing for essential medications.
Concerns regarding the long-term impact of the deal are centered on patient outcomes. Analysis suggests the agreement could lead to 229,000 excess deaths by 2036 [1]. This projection is based on the potential for reduced access to critical medicines, and the financial strain placed on public health services.
The groups urging the reversal seek to ensure that patient care remains the primary objective of national health policy. They said the current trajectory of the trade deal risks undermining the core mission of the NHS by favoring corporate interests over clinical needs [1].
Burnham now faces pressure to address these concerns as he manages the transition of leadership. The medical community said that scrapping the deal is necessary to prevent the projected rise in deaths and to protect the sustainability of the public health system [1].
“"dangerous"”
This conflict highlights the tension between international trade liberalization and the maintenance of a single-payer healthcare system. If the UK continues to align its pharmaceutical procurement with US-style market dynamics, it may lose the bulk-purchasing leverage that currently keeps drug costs lower than in the American market, potentially creating a public health crisis based on affordability.
